We do not diagnose disease or recommend a dietary supplement for the treatment of disease. You should share this information with your physician who can determine what nutrition, disease and injury treatment regimen is best for you. You can search this site or the web for topics of interest that I may have written (use Dr Simone and topic).
“We provide truthful information without emotion or influence from the medical establishment, pharmaceutical industry, national organizations, special interest groups or government agencies.” Charles B Simone, M.MS., M.D.
THE TRUTH ABOUT CANCER
Lawrenceville, NJ (Dr Charles Simone) – In 1996, Dr Charles Simone outlined for NBC, THE TRUTH ABOUT CANCER. Unfortunately, the information is timeless.
Despite the enormous effort to combat cancer, the number of new cases of nearly every form of cancer has increased. From 1930 to the present, despite the introduction of radiation therapy, chemotherapy, and immunotherapy with biologic response modifiers, despite CT scans, MRI scans, and all the other new medical technology, lifespans for people with almost every form of cancer have remained constant, that means there has been no significant progress in treatment for adult cancer, except for those who change their lifestyle (Ten Point Plan) that enhances their immune system and does not feed the cancer.
Also, in 1996 Dr Charles Simone outlined the tremendous conflict of interest between Big Pharma and Memorial Sloan Kettering Cancer Center. And the conflict of interest continues between Big Pharma and some cancer centers and some physicians.
REMEMBER, THIS INTERVIEW WAS DONE IN 1996. BUT, UNFORTUNATELY, THE INFORMATION IS TIMELESS – BOTH THE TRUTH ABOUT CANCER and THE CONFLICT OF INTEREST BETWEEN BIG PHARMA AND SOME CANCER CENTERS AND SOME PHYSICIANS.
On September 8, 2018 the New York Times and ProPublica reported that Memorial Sloan Kettering Cancer Center’s chief medical officer, Dr. José Baselga, failed to disclose millions of dollars’ worth of payments from pharmaceutical and other health care companies, and did not disclose his financial ties from dozens of research articles in prestigious publications like The New England Journal of Medicine and The Lancet.
He has held board memberships or advisory roles with Roche and Bristol-Myers Squibb, among other corporations, has had a stake in start-ups testing cancer therapies, and played a key role in the development of drugs. He also omitted payments he received from companies connected to cancer research in his articles published in the group’s journal, Cancer Discovery. At the same time, he has been one of the journal’s two editors in chief.
On September 13, 2018 he resigned from Memorial Sloan Ketteringand Bristol Myers Squib.